Newswise — SAN ANTONIO — Now in its 34th year, the 2011 CTRC-AACR San Antonio Breast Cancer Symposium will focus on emerging treatments in hard-to-treat populations, including patients with metastatic breast cancer, and on new knowledge about prevention and risk.
The symposium will be held at the Henry B. Gonzales Convention Center in San Antonio during Dec. 6-10, 2011.
The symposium is presented by the Cancer Therapy & Research Center at University of Texas Health Science Center at San Antonio, the American Association for Cancer Research and Baylor College of Medicine. The driving force behind this collaboration is the shared mission of the organizations to advance progress in breast cancer research.
To help guide coverage for the news media, the AACR Office of Communications will operate a full-service press room in Room 217A-C of the convention center.
New research will be presented during the following five press conferences held in Room 217D. Reporters who cannot attend in person can call in using the following information:
• U.S./Canada (Toll Free): 1 (888) 647-7462• International (Toll): 1 (201) 604-0169
The meeting will open with a press conference on Wednesday, Dec. 7, 2011, at 7:30 a.m. CT, hosted by Jennifer Ligibel, M.D., a breast oncologist and assistant professor of medicine at the Dana-Farber Cancer Institute. The press conference will focus on the following research:
• Diabetes and Obesity Increase Risk for Breast Cancer Development• Molecular Differences May Be Used to Predict Early vs. Late Hormone Receptor-Positive Breast Cancer Recurrence • Brachytherapy Was Associated With Twofold Increased Risk for Mastectomy, Complications • New Test Predicts Risk for Recurrence for Patients With DCIS
Later that afternoon, at 12:30 p.m. CT, the Institute of Medicine will present a report entitled, “Breast Cancer and the Environment: A Life Course Approach.” More information can be found here.
Finally, at 5:00 p.m. CT, James Ingle, M.D., professor of oncology at the Mayo Clinic in Rochester, will host a media availability on important new research in bisphosphonates and breast cancer, which will feature the following research:
• Zoledronic Acid Shows Long-Term Benefit in Survivorship for Premenopausal ER-Positive Breast Cancer • Clodronate Appeared Safe, Modestly Affected Breast Cancer Disease Events• Immediate Bisphosphonate Use With Endocrine Therapy Reduced Recurrence, Increased Survival in Postmenopausal Early Breast Cancer • Oral Bisphosphonate Did Not Improve Prognosis for Patients With Breast Cancer
On Thursday, Dec. 8, 2011, at 7:30 a.m. CT, Lisa A. Carey, M.D., Preyer distinguished professor in breast cancer research at the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, will host a press conference featuring late-stage clinical trials in hard-to-treat populations. The press conference will feature the following research:
• Dual HER2 Blockade Significantly Extends Progression-Free Survival • Exemestane Plus Everolimus Increased Progression-Free Survival for Women With Metastatic Breast Cancer • Addition of Bevacizumab to Conventional Therapy Improved Progression-Free Survival in HER2-Positive Breast Cancer
At 12:30 p.m. CT, on Thursday, Dec. 8, 2011, Patricia Ganz, M.D., professor at the UCLA Schools of Medicine and Public Health and director of the division of cancer prevention and control research at the Jonsson Comprehensive Cancer Center, will host a press conference on issues in genetics and socioeconomics that will feature the following research:
• Risk for Developing New Cancer in Other Breast Increased for Survivors With BRCA Mutation • Many Women Do Not Undergo Breast Reconstruction After Mastectomy • Bilateral Oophorectomy Associated With Higher Prevalence of Low Bone Mineral Density and Arthritis in Younger Women
In addition to the press conferences, the 2011 CTRC-AACR San Antonio Breast Cancer Symposium has identified the following research as newsworthy:
• Starch Intake May Influence Risk for Breast Cancer Recurrence • Intermittent, Low-Carbohydrate Diets More Successful Than Standard Dieting, Present Possible Intervention for Breast Cancer Prevention • Addition of Trastuzumab May Potentially Equalize Disease-Free Survival Outcomes Among Obese and Normal-Weight Patients • MRI May Be Noninvasive Method to Measure Breast Cancer Prognosis • Obesity Linked to Worse Outcomes in Early Breast Cancer Treatment• Breast Cancer Mortality Higher in Hispanic Women
# # #
The mission of the CTRC-AACR San Antonio Breast Cancer Symposium is to produce a unique and comprehensive scientific meeting that encompasses the full spectrum of breast cancer research, facilitating the rapid translation of new knowledge into better care for patients with breast cancer. The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, the American Association for Cancer Research (AACR) and Baylor College of Medicine are joint sponsors of the San Antonio Breast Cancer Symposium. This collaboration utilizes the clinical strengths of the CTRC and Baylor and the AACR’s scientific prestige in basic, translational and clinical cancer research to expedite the delivery of the latest scientific advances to the clinic. The 34th annual symposium is expected to draw nearly 8,000 participants from more than 90 countries.
RSS